ReviewThe oncologist2010
Current management of gallbladder carcinoma.
Review in The oncologist, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
174 citing papers in PubMed, 2 syntheses or guidelines pooled it, 345 citations in OpenAlex.
- Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.The Cochrane database of systematic reviews · 2018Pooled it
- Association between glutathione S-transferase M1 null genotype and risk of gallbladder cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer.Cancer reports (Hoboken, N.J.) · 2026Review
- Prognostic Value of Perioperative Inflammatory-Immune-Nutritional Indicators in Advanced Gallbladder Cancer.Cancer medicine · 2026Article
- Efficacy and Safety of First-Line Chemotherapy With Gemcitabine Plus Nab-Paclitaxel in Unresectable Gallbladder Cancer.Cancer medicine · 2026Article
- Transcriptional landscape of coding-noncoding RNA interactions in gallstone-associated and de-novo gallbladder carcinoma.Functional & integrative genomics · 2026Article
- Comparative analysis of genomic profiles and clinical outcomes in cholangiocarcinoma and gallbladder cancer.Scientific reports · 2026Article
- Gallbladder carcinoma in Brazil: Clinicopathological profile and survival outcomes from a high-volume cancer center.World journal of gastroenterology · 2026Article
- A prospective pilot study to evaluate the impact of palliative radiotherapy in upfront inoperable/chemo unfit patients with extrahepatic biliary tract tumors.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Article
- "Rapid progression of gallbladder cancer from stage I to stage IV in 4-months: A case highlighting the critical need for timely intervention".Radiology case reports · 2025Article
- Extended versus simple cholecystectomy in stage I gallbladder cancer: a SEER-based competing risk analysis with external validation.World journal of surgical oncology · 2025Article
- Gallbladder Cancer and Peritoneal Metastasis: Is there any role of Cytoreductive Surgery (CRS) and/or Hyperthermic Intraperitoneal Chemotherapy (HIPEC)? A Narrative Review.Journal of gastrointestinal cancer · 2025Review
- Multidisciplinary management of surgery and postoperative recurrence in stage IV gallbladder cancer following conversion therapy: a case report.Frontiers in oncology · 2025Article
- Quantitative MRCP metrics as imaging biomarkers to differentiate benign from malignant bile duct obstructions.Frontiers in oncology · 2025Article
- Hotspots and scientometrics in gallbladder cancer surgery research: a bibliometric and visualization analysis (2014-2024).Frontiers in oncology · 2025Article
- Epidermal Growth Factor Receptor (EGFR) and SMAD4 negatively correlated in the progression of gallbladder cancer in Eastern Indian patients.BMC gastroenterology · 2024Article
- A Single-Center Analysis of Patient Characteristics and Overall Survival in Patients with Resectable Gallbladder Cancer.Healthcare (Basel, Switzerland) · 2024Article
- Gallbladder cancer: Progress in the Indian subcontinent.World journal of clinical oncology · 2024Review
- Prognostic Insights and Survival Analysis of Gallbladder Cancer in Bihar, India: a Prospective Observational Study Emphasizing the Impact of Surgical Intervention on Overall Survival.Indian journal of surgical oncology · 2024Article
- Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy and intraoperative radiation therapy in the management of gallbladder cancer: a case report.Frontiers in oncology · 2024Article
114 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallbladder cancer (GBC) represents the most common and aggressive type among the biliary tree cancers (BTCs). Complete surgical resection offers the only chance for cure; however, only 10% of patients with GBC present with early-stage disease and are considered surgical candidates. Among those patients who do undergo "curative" resection, recurrence rates are high. There are no established adjuvant treatments in this setting. Patients with unresectable or metastatic GBC have a poor prognosis. There has been a paucity of randomized phase III data in this field. A recent report demonstrated longer overall survival with gemcitabine in combination with cisplatin than with gemcitabine alone in patients with advanced or metastatic BTCs. Molecularly targeted agents are under development. In this review, we attempt to discuss the current status and key issues involved in the management of GBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.